Pancreatic Cancer
p8 proposed as new target of gemcitabine in pancreatic cancer cells
Published in Cancer Weekly, March 14th, 2006
According to a study from France, "Gemcitabine is the only available chemotherapeutic treatment of pancreatic cancers. It is, however, moderately effective, showing a tumor response rate of only 12%."
"The aim of this work was to identify new pathways involved in the resistance of pancreatic cancer cells to gemcitabine, in the hope of developing new adjuvant strategies to enhance its therapeutic efficacy. Comparison of gene expression patterns of five human pancreatic cancer cell lines showing different degrees of resistance to gemcitabine revealed specific overexpression of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-03-14)
More Articles from Cancer Weekly
- Clinical Trials
Strategy to recruit Asian Americans for cancer clinical trials discussed - Melanoma
Integrin alphavbeta3 and cofilin modulate K1735 melanoma cell invasion - Prostate Cancer
P1NP used to predict metastases, progression, and survival in prostate cancer - Adverse Drug Reaction
Osteonecrosis of the jaw related to pamidronate therapy - Antibiotics
Antibiotic use and survival in advanced cancer patients with infections examined - Antiretroviral Therapy
Ritonavir has potent anti-NF-kappa B and antitumor effects - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
